Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.89 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.89 |
| ▸ | CHAT | P28329 | 2/20 | 0.89 |
| ▸ | AURKA | O14965 | 2/20 | 0.89 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.89 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.89 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124919 | 0.95 | EP300 (0.86) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL16215999 | 0.95 | EP300 (0.89) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL9945415 | 0.95 | EP300 (0.88) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL17856796 | 0.95 | EP300 (0.88) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL14124844 | 0.95 | EP300 (0.88) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL18812028 | 0.94 | EP300 (0.90) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL14124851 | 0.94 | EP300 (0.86) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL29450543 | 0.94 | CHAT (0.90) | EP300NAA50CHATAURKAKAT5 | |
| Coenzyme_A SCHEMBL26752 | 0.94 | EP300 (1.00) | EP300NAA50CHATAURKAKAT5 | |
| SCHEMBL18803179 | 0.94 | EP300 (0.91) | EP300NAA50CHATAURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140330246-A1 | Intrauterine fetal growth restriction - The biochemical rationale of treatment modalities including extraperitoneal transamniotic fetal supplements | PATURU SUMATHI (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330246-A1 | Intrauterine fetal growth restriction - The biochemical rationale of treatment modalities including extraperitoneal transamniotic fetal supplements | ALPP, SLC2A1, SLC2A2 | EP300 639/4885NAA50 1086/4885CHAT 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.